Euglycemic Diabetic Ketoacidosis in a Patient with Type 2 Diabetes and Preserved Insulin Secretion on Empagliflozin.
Empagliflozin治療下,具保留胰島素分泌功能之第二型糖尿病患者發生正血糖性糖尿病酮酸中毒
Intern Med 2025-04-29
Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR-HF2-DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials.
鐵羧基麥芽糖(Ferric carboxymaltose)於缺鐵與慢性心臟衰竭患者之發病率與死亡率評估(FAIR-HF2-DZHK05)試驗:基線特徵及與其他相關臨床試驗之比較
Eur J Heart Fail 2025-04-29
Initial Pharmacological Strategies in People with Early Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis.
早期第二型糖尿病患者的初始藥物治療策略:系統性回顧與網絡統合分析
Diabetes Metab J 2025-04-29
Pentraxin-3 as a Biomarker in Diabetes Mellitus: Insights into Inflammation, Vascular Complications, and Modulation by Antidiabetic Medications.
Pentraxin-3 作為糖尿病的生物標記:對發炎、血管併發症及抗糖尿病藥物調節作用的深入探討
Biomedicines 2025-04-29
Cost-Effectiveness Analysis of SGLT2 Inhibitors for Cardio-Renal-Metabolic Disease Based on Data from Japanese Studies.
基於日本研究數據之SGLT2抑制劑用於心腎代謝疾病的成本效益分析
Adv Ther 2025-04-29
Trends in first-line glucose-lowering medication use among US adults with type 2 diabetes from 2019 to 2023.
2019年至2023年間美國成人第二型糖尿病患者第一線降血糖藥物使用趨勢
J Manag Care Spec Pharm 2025-04-29
Association between the body mass index and risk of cardiovascular events in sodium-glucose cotransporter 2 inhibitor users compared with dipeptidyl-peptidase 4 inhibitor users: A nationwide cohort study in Korea.
韓國全國性世代研究:身體質量指數與SGLT2抑制劑使用者相比DPP-4抑制劑使用者心血管事件風險之關聯
Diabetes Obes Metab 2025-04-28